UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 267

Sortiert nach

Editorial: 5‐ASA in IBD patients on biologics—‘stop or continue’?

Alimentary pharmacology & therapeutics, 2021-09, Vol.54 (6), p.843-844

2021

Volltextzugriff (PDF)

Editorial: anti‐TNF agents against vedolizumab as a second‐line treatment? Not surprising tie game

Alimentary pharmacology & therapeutics, 2021-03, Vol.53 (5), p.640-641

2021

Volltextzugriff (PDF)

Use of imaging modalities for decision-making in inflammatory bowel disease

Therapeutic Advances in Gastroenterology, 2023-01, Vol.16, p.17562848231151293-17562848231151293

2023

Volltextzugriff (PDF)

Selective Autophagy Receptors in Antiviral Defense

Trends in microbiology (Regular ed.), 2021-09, Vol.29 (9), p.798-810

2021

Volltextzugriff (PDF)

Comparison of short‐ and long‐term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor therapy

Alimentary Pharmacology & Therapeutics (Suppl), 2021-06, Vol.53 (12), p.1289-1299

2021

Volltextzugriff (PDF)

A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities

Journal of Crohn's and colitis, 2021-01, Vol.15 (1), p.152-161

2021

Volltextzugriff (PDF)

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Clinical gastroenterology and hepatology, 2017-11, Vol.15 (11), p.1750-1757.e3

2017

Volltextzugriff (PDF)

Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial

Gut, 2020-07, Vol.69 (7), p.1206

2020

Volltextzugriff (PDF)

The Kynurenine Pathway and Cancer: Why Keep It Simple When You Can Make It Complicated

Cancers, 2022-06, Vol.14 (11), p.2793

2022

Volltextzugriff (PDF)

No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification

Digestive diseases and sciences, 2021-08, Vol.66 (8), p.2744-2749

2021

Volltextzugriff (PDF)

Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study

Alimentary Pharmacology & Therapeutics (Suppl), 2023-06, Vol.57 (11), p.1290-1298

2023

Volltextzugriff (PDF)

Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease

The American journal of gastroenterology, 2020-07, Vol.115 (7), p.1084

2020

Volltextzugriff (PDF)

Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease

Clinical gastroenterology and hepatology, 2019-11, Vol.17 (12), p.2610-2612

2019

Volltextzugriff (PDF)

Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional Study

Inflammatory bowel diseases, 2024-02

2024

Volltextzugriff (PDF)

Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn’s Disease

Digestive diseases and sciences, 2021-12, Vol.66 (12), p.4429-4435

2021

Volltextzugriff (PDF)

Prevalence of the Oral Corticosteroid Exposure and Excessive Use in Patients with Inflammatory Bowel Disease: Data from Four French Referral Centers of the International DICE Study

Journal of clinical medicine, 2024-05, Vol.13 (9), p.2652

2024

Volltextzugriff (PDF)

Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2024-05, Vol.18 (5), p.679-685

2024

Volltextzugriff (PDF)

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial

Clinical gastroenterology and hepatology, 2020-06, Vol.18 (7), p.1553-1560.e1

2020

Volltextzugriff (PDF)

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study

Alimentary pharmacology & therapeutics, 2020-01, Vol.51 (1), p.129-138

2020

Volltextzugriff (PDF)

Impaired reprogramming of the autophagy flux in maturing dendritic cells from crohn disease patients with core autophagy gene-related polymorphisms

Autophagy, 2024-08, Vol.20 (8), p.1837-1853

2024

Volltextzugriff (PDF)

Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study

Inflammatory bowel diseases, 2017-11, Vol.23 (11), p.2048-2053

2017

Volltextzugriff (PDF)

Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels

Inflammatory bowel diseases, 2022-05, Vol.28 (5), p.720-727

2022

Volltextzugriff (PDF)

Relationships of circulating CD4+ T cell subsets and cytokines with the risk of relapse in patients with Crohn’s disease

Frontiers in immunology, 2022-11, Vol.13, p.864353-864353

2022

Volltextzugriff (PDF)

1 – 25 von 267

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(244)
Mit Volltextzugriff
(233)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Editorial: 5‐ASA in IBD patients on biologics—‘stop or continue’?

Editorial: anti‐TNF agents against vedolizumab as a second‐line treatment? Not surprising tie game

Use of imaging modalities for decision-making in inflammatory bowel disease

Selective Autophagy Receptors in Antiviral Defense

Comparison of short‐ and long‐term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor therapy

A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial

The Kynurenine Pathway and Cancer: Why Keep It Simple When You Can Make It Complicated

No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification

Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study

Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease

Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease

Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease

Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional Study

Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn’s Disease

Prevalence of the Oral Corticosteroid Exposure and Excessive Use in Patients with Inflammatory Bowel Disease: Data from Four French Referral Centers of the International DICE Study

Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study

Impaired reprogramming of the autophagy flux in maturing dendritic cells from crohn disease patients with core autophagy gene-related polymorphisms

Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study

Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study

Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels

Relationships of circulating CD4+ T cell subsets and cytokines with the risk of relapse in patients with Crohn’s disease

Suchergebnisse filtern